gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLC10.22416/1382-4376-2022-32-2-85-92gastro-j-664Research ArticleНАЦИОНАЛЬНАЯ ШКОЛА ГАСТРОЭНТЕРОЛОГИИ, ГЕПАТОЛОГИИNATIONAL COLLEGE OF GASTROENTEROLOGY, HEPATOLOGYПандемия COVID-19 и синдром раздраженного кишечника — есть ли связь?COVID-19 Pandemic and Irritable Bowel Syndrome — is there a Relationship?https://orcid.org/0000-0002-7603-8481АхмедовВ. А.AkhmedovV. A.

Ахмедов Вадим Адильевич — доктор медицинских наук, профессор, заведующий кафедрой медицинской реабилитации дополнительного профессионального образования

644099, г. Омск , ул. Ленина 12

Vadim A. Akhmedov — Dr. Sci. (Med.), Prof., Head of the Chair of Medical Rehabilitation of Additional Professional Education

644099, Omsk, Lenina str., 12

v_akhmedov@mail.ruФГБОУ ВО «Омский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияOmsk State Medical UniversityRussian Federation2022150520223228592Copyright © Ахмедов В.А., 20222022Ахмедов В.А.Akhmedov V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/664Цель обзора

Цель обзора: отразить особенности течения синдрома раздраженного кишечника (СРК) в период пандемии COVID-19.

Основные положения

Основные положения. Отмечено, что COVID-19 может способствовать формированию постинфекционных функциональных желудочно-кишечных заболеваний из-за ряда предрасполагающих факторов. Рецепторы ангиотензинпревращающего фермента-2 (АПФ-2), место связывания вируса SARS-CoV-2 с клетками организма человека, присутствуют в эпителиальных клетках кишечника; вирус был обнаружен в кале примерно у половины пациентов. Желудочно-кишечные симптомы, в том числе диарея, возникают примерно у одной пятой пациентов. Фекальный кальпротектин, маркер воспаления ЖКТ, повышен у пациентов с COVID-19. У пациентов отмечены макроскопические и микроскопические признаки повреждения слизистой оболочки ЖКТ. COVID-19 ассоциирован с изменением кишечной микробиоты. В условиях пандемии COVID-19 у более чем 90 % из опрошенных пациентов с СРК выявлено обострение заболевания с усилением боли и вздутия живота.

Заключение

Заключение. Ведение пациентов с СРК в условиях пандемии COVID-19 диктует необходимость комплексного подхода. Примером мультитаргетного препарата, оказывающего влияние на различные патогенетические факторы функциональных заболеваний ЖКТ, служит препарат Колофорт®.

The aim

The aim: to reflect the features of the course of irritable bowel syndrome during the COVID-19 pandemic.

Key points

Key points. It has been noted that the COVID-19 may contribute to the formation of post-infectious functional gastrointestinal diseases, given that angiotensin-converting enzyme-2 (ACE-2) receptors, the site of binding of the SARS-CoV-2 virus to human cells, are also present in epithelial intestinal cells; virus was found in feces in about half of patients, gastrointestinal symptoms, including diarrhea occur in about one fifth of patients, fecal calprotectin, a marker of GI inflammation is elevated in patients with COVID-19, macroscopically as well as histologically, patients show signs of damage mucous membrane of the gastrointestinal tract, and also, as noted above, they have a dysbiosis of the intestinal microbiota.

Conclusion

Conclusion. It was shown that during the pandemic, more than 90 % of the interviewed patients with IBS had an exacerbation of IBS with an increase in symptoms such as bloating and cramps, and 75 % of them said that the exacerbation of symptoms was reflected in the activity of patients in everyday life. These factors dictate the need for an integrated approach in the management of such a group of patients with the use of modern multi-target drugs that affect the pathogenetic factors in the formation of functional gastrointestinal diseases, one of which is the Kolofort drug due to the triple multi-target mechanism of action on the pathogenesis of functional gastrointestinal diseases. 

синдром раздраженного кишечникаCOVID-19микробиотастрессдисбиозКолофорт®irritable bowel syndromeCOVID-19microbiotastressdysbiosisKolofortПубликация выполнена при поддержке «Материа Медика».Publication was supported by “Materia Medica”.ReferencesMunster V.J., Feldmann F., Williamson B.N., van Doremalen N., Perez-Perez L., Schulz J., et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. 2020;585(7824):268–72. DOI: 10.1038/s41586-020-2324-7Munster V.J., Feldmann F., Williamson B.N., van Doremalen N., Perez-Perez L., Schulz J., et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. 2020;585(7824):268–72. DOI: 10.1038/s41586-020-2324-7Hamid S., Mir M. Y., Rohela G.K. Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics). New Microbes New Infect. 2020;35:100679. DOI: 10.1016/j.nmni.2020.100679Hamid S., Mir M. Y., Rohela G.K. Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics). New Microbes New Infect. 2020;35:100679. DOI: 10.1016/j.nmni.2020.100679D’Amico F., Baumgart D.C., Danese S., Peyrin-Biroulet L. Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. Clin Gastroenterol Hepatol. 2020;18(8):1663–72. DOI: 10.1016/j. cgh.2020.04.001D’Amico F., Baumgart D.C., Danese S., Peyrin-Biroulet L. Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. Clin Gastroenterol Hepatol. 2020;18(8):1663–72. DOI: 10.1016/j. cgh.2020.04.001Ianiro G., Mullish B.H., Kelly C.R., Sokol H., Kassam Z., Ng S.C., et al. Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. Lancet Gastroenterol Hepatol. 2020;5(5):430–2. DOI: 10.1016/S2468-1253(20)30082-0Ianiro G., Mullish B.H., Kelly C.R., Sokol H., Kassam Z., Ng S.C., et al. Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. Lancet Gastroenterol Hepatol. 2020;5(5):430–2. DOI: 10.1016/S2468-1253(20)30082-0Takakura W., Pimentel M. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome — An Update. Front Psychiatry. 2020;11:664. DOI: 10.3389/fpsyt.2020.00664Takakura W., Pimentel M. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome — An Update. Front Psychiatry. 2020;11:664. DOI: 10.3389/fpsyt.2020.00664Klem F., Wadhwa A., Prokop L.J., Sundt W.J. Farrugia G., Camilleri M., et al. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis. Gastroenterology 2017;152:1042–54. DOI: 10.1053/j.gastro.2016.12.039Klem F., Wadhwa A., Prokop L.J., Sundt W.J. Farrugia G., Camilleri M., et al. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis. Gastroenterology 2017;152:1042–54. DOI: 10.1053/j.gastro.2016.12.039Ghoshal U.C., Ranjan P. Post-infectious irritable bowel syndrome: the past, the present and the future. J Gastroenterol Hepatol. 2011;26 (Suppl 3):94–101. DOI: 10.1111/j.1440-1746.2011.06643.xGhoshal U.C., Ranjan P. Post-infectious irritable bowel syndrome: the past, the present and the future. J Gastroenterol Hepatol. 2011;26 (Suppl 3):94–101. DOI: 10.1111/j.1440-1746.2011.06643.xSchmulson M., Ghoshal U.C., Barbara G. Managing the inevitable surge of post-COVID-19 functional gastrointestinal disorders. Am J Gastroenterol. 2021;116:4–7. DOI: 10.14309/ajg.0000000000001062Schmulson M., Ghoshal U.C., Barbara G. Managing the inevitable surge of post-COVID-19 functional gastrointestinal disorders. Am J Gastroenterol. 2021;116:4–7. DOI: 10.14309/ajg.0000000000001062Ghoshal U.C., Ghoshal U., Mathur A., Singh R.K., Nath A.K., Garg A., et al. The spectrum of gastrointestinal symptoms in patients with coronavirus disease-19: predictors, relationship with disease severity, and outcome. Clin Transl Gastroenterol. 2020;11:e00259. DOI: 10.14309/ ctg.0000000000000259Ghoshal U.C., Ghoshal U., Mathur A., Singh R.K., Nath A.K., Garg A., et al. The spectrum of gastrointestinal symptoms in patients with coronavirus disease-19: predictors, relationship with disease severity, and outcome. Clin Transl Gastroenterol. 2020;11:e00259. DOI: 10.14309/ ctg.0000000000000259Wan Y., Shang J., Graham R., Baric R.S., Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol 2020;94:e00127-20. DOI: 10.1128/JVI.00127-20Wan Y., Shang J., Graham R., Baric R.S., Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol 2020;94:e00127-20. DOI: 10.1128/JVI.00127-20Wong M.C., Huang J., Lai C., Ng R., Chan F.K., Chan P.K. Detection of SARS-CoV-2 RNA in fecal specimens of patients with confirmed COVID-19: a meta-analysis. J Infect 2020;81:e31–8. DOI: 10.1128/JVI.00127-20Wong M.C., Huang J., Lai C., Ng R., Chan F.K., Chan P.K. Detection of SARS-CoV-2 RNA in fecal specimens of patients with confirmed COVID-19: a meta-analysis. J Infect 2020;81:e31–8. DOI: 10.1128/JVI.00127-20Cardinale V., Capurso G., Ianiro G., Gasbarrini A., Arcidiacono P.G., Alvaro D. Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: a working hypothesis. Dig Liver Dis. 2020;52:1383–9. DOI: 10.1016/j.dld.2020.09.009Cardinale V., Capurso G., Ianiro G., Gasbarrini A., Arcidiacono P.G., Alvaro D. Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: a working hypothesis. Dig Liver Dis. 2020;52:1383–9. DOI: 10.1016/j.dld.2020.09.009Hanning N., Edwinson A.L., Ceuleers H., Peters S.A., De Man J.G., Hassett L.C., et al. Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review. Therap Adv Gastroenterol. 2021;14:1756284821993586. DOI: 10.1177/1756284821993586Hanning N., Edwinson A.L., Ceuleers H., Peters S.A., De Man J.G., Hassett L.C., et al. Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review. Therap Adv Gastroenterol. 2021;14:1756284821993586. DOI: 10.1177/1756284821993586Gwee K.A., Collins S.M., Read N.W., Rajnakova A., Deng Y., Graham J.C., et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired postinfectious irritable bowel syndrome. Gut. 2003;52(4):523–6. DOI: 10.1136/gut.52.4.523Gwee K.A., Collins S.M., Read N.W., Rajnakova A., Deng Y., Graham J.C., et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired postinfectious irritable bowel syndrome. Gut. 2003;52(4):523–6. DOI: 10.1136/gut.52.4.523Downs I.A., Aroniadis O.C., Kelly L., Brandt L.J. Postinfection irritable bowel syndrome: the links between gastroenteritis, inflammation, the microbiome, and functional disease. J Clin Gastroenterol. 2017;51:869–77. DOI: 10.1097/MCG.0000000000000924Downs I.A., Aroniadis O.C., Kelly L., Brandt L.J. Postinfection irritable bowel syndrome: the links between gastroenteritis, inflammation, the microbiome, and functional disease. J Clin Gastroenterol. 2017;51:869–77. DOI: 10.1097/MCG.0000000000000924Villani A.C., Lemire M., Thabane M., Belisle A., Geneau G. , Garg A.X., et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology. 2010;138:1502–13. DOI: 10.1053/j.gastro.2009.12.049Villani A.C., Lemire M., Thabane M., Belisle A., Geneau G. , Garg A.X., et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology. 2010;138:1502–13. DOI: 10.1053/j.gastro.2009.12.049Tang H.Y., Jiang A.J., Wang X.Y., Wang H., Guan Y.Y., Li F., et al. Uncovering the pathophysiology of irritable bowel syndrome by exploring the gut-brain axis: a narrative review. Ann Transl Med. 2021;9(14):1187. DOI: 10.21037/atm-21-2779Tang H.Y., Jiang A.J., Wang X.Y., Wang H., Guan Y.Y., Li F., et al. Uncovering the pathophysiology of irritable bowel syndrome by exploring the gut-brain axis: a narrative review. Ann Transl Med. 2021;9(14):1187. DOI: 10.21037/atm-21-2779Barbara G., Grover M., Bercik P., Corsetti M., Ghoshal U.C., Ohman L., et al. Rome Foundation Working Team report on post-infection irritable bowel syndrome. Gastroenterology 2019;156(1):46–58. DOI: 10.1053/j.gastro.2018.07.011Barbara G., Grover M., Bercik P., Corsetti M., Ghoshal U.C., Ohman L., et al. Rome Foundation Working Team report on post-infection irritable bowel syndrome. Gastroenterology 2019;156(1):46–58. DOI: 10.1053/j.gastro.2018.07.011Ghoshal U.C., Shukla R., Ghoshal U., Gwee K.A., Ng S.C., Quigley E.M. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam 2012;2012:151085. DOI: 10.1155/2012/151085Ghoshal U.C., Shukla R., Ghoshal U., Gwee K.A., Ng S.C., Quigley E.M. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam 2012;2012:151085. DOI: 10.1155/2012/151085Ong J., Young B.E., Ong S. COVID-19 in gastroenterology: a clinical perspective. Gut. 2020;69:1144–5. DOI: 10.1136/gutjnl-2020-321051Ong J., Young B.E., Ong S. COVID-19 in gastroenterology: a clinical perspective. Gut. 2020;69:1144–5. DOI: 10.1136/gutjnl-2020-321051Gu S., Chen Y., Wu Z., Chen Y., Gao H., Lv L., et al. Alterations of the gut microbiota in patients with COVID-19 or H1N1 influenza. Clin Infect Dis. 2020;71(10):2669–78. DOI: 10.1093/cid/ciaa709Gu S., Chen Y., Wu Z., Chen Y., Gao H., Lv L., et al. Alterations of the gut microbiota in patients with COVID-19 or H1N1 influenza. Clin Infect Dis. 2020;71(10):2669–78. DOI: 10.1093/cid/ciaa709Rodrigues P.B., Dos Santos Pereira Gomes A.B., Genaro L.M., Pascoal L.B., de Souza A.P., Leal R.F. Intestinal Microbiota in the SARS-CoV-2 Infection: What Is Known? Adv Exp Med Biol. 2021;1327:93–106. DOI: 10.1007/978-3-030-71697-4_7Rodrigues P.B., Dos Santos Pereira Gomes A.B., Genaro L.M., Pascoal L.B., de Souza A.P., Leal R.F. Intestinal Microbiota in the SARS-CoV-2 Infection: What Is Known? Adv Exp Med Biol. 2021;1327:93–106. DOI: 10.1007/978-3-030-71697-4_7Tian Y., Sun K.Y., Meng T.Q., Guo S.M., Li G.M., Xiong G.L., et al. Gut Microbiota May Not Be Fully Restored in Recovered COVID-19 Patients After 3-Month Recovery. Front Nutr. 2021;8:638825. DOI: 10.3389/fnut.2021.638825Tian Y., Sun K.Y., Meng T.Q., Guo S.M., Li G.M., Xiong G.L., et al. Gut Microbiota May Not Be Fully Restored in Recovered COVID-19 Patients After 3-Month Recovery. Front Nutr. 2021;8:638825. DOI: 10.3389/fnut.2021.638825Gaibani P., D’Amico F., Bartoletti M., Lombardo D., Rampelli S., Fornaro G., et al. The Gut Microbiota of Critically Ill Patients With COVID-19. Front Cell Infect Microbiol. 2021;11:670424. DOI: 10.3389/fcimb.2021.670424Gaibani P., D’Amico F., Bartoletti M., Lombardo D., Rampelli S., Fornaro G., et al. The Gut Microbiota of Critically Ill Patients With COVID-19. Front Cell Infect Microbiol. 2021;11:670424. DOI: 10.3389/fcimb.2021.670424Sokol H., Contreras V., Maisonnasse P., Desmons A., Delache B., Sectio V., et al. SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota. Gut Microbes. 2021;13(1):1–19. DOI: 10.1080/19490976.2021.1893113Sokol H., Contreras V., Maisonnasse P., Desmons A., Delache B., Sectio V., et al. SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota. Gut Microbes. 2021;13(1):1–19. DOI: 10.1080/19490976.2021.1893113Chen J., Hall S., Vitetta L. Altered gut microbial metabolites could mediate the effects of risk factors in Covid-19. Rev Med Virol. 2021;31(5):1–13. DOI: 10.1002/rmv.2211Chen J., Hall S., Vitetta L. Altered gut microbial metabolites could mediate the effects of risk factors in Covid-19. Rev Med Virol. 2021;31(5):1–13. DOI: 10.1002/rmv.2211Zhou Y., Zhang J., Zhang D. Ma V.L., Wang X., et al. Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge. Microbiol. 2021;59(10):941–8. DOI: 10.1007/s12275-021-1206-5Zhou Y., Zhang J., Zhang D. Ma V.L., Wang X., et al. Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge. Microbiol. 2021;59(10):941–8. DOI: 10.1007/s12275-021-1206-5Yamamoto S., Saito M., Tamura A., Prawisuda D, Mizutani T., Yotsuyanagi H. The human microbiome and COVID-19: A systematic review. PLoS One. 2021;16(6):e0253293. DOI: 10.1371/journal.pone.0253293Yamamoto S., Saito M., Tamura A., Prawisuda D, Mizutani T., Yotsuyanagi H. The human microbiome and COVID-19: A systematic review. PLoS One. 2021;16(6):e0253293. DOI: 10.1371/journal.pone.0253293Zuo T., Zhang F., Lui G.C., Yeoh Y.K., Li A.Y.L., Zhan H., et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology 2020;159:944–55.e8. DOI: 10.1053/j.gastro.2020.05.048Zuo T., Zhang F., Lui G.C., Yeoh Y.K., Li A.Y.L., Zhan H., et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology 2020;159:944–55.e8. DOI: 10.1053/j.gastro.2020.05.048Cardinale V., Capurso G., Ianiro G., Gasbarrin A., Arcidiacono P.G., Alvaro D. Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: A working hypothesis. Dig Liver Dis. 2020;52(12):1383–9. DOI: 10.1016/j.dld.2020.09.009Cardinale V., Capurso G., Ianiro G., Gasbarrin A., Arcidiacono P.G., Alvaro D. Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: A working hypothesis. Dig Liver Dis. 2020;52(12):1383–9. DOI: 10.1016/j.dld.2020.09.009Effenberger M., Grabherr F., Mayr L., Schwaerzler J., Nairz M., Seifert M., et al. Faecal calprotectin indicates intestinal inflammation in COVID-19. Gut. 2020;69:1543–4. DOI: 10.1136/gutjnl-2020-321388Effenberger M., Grabherr F., Mayr L., Schwaerzler J., Nairz M., Seifert M., et al. Faecal calprotectin indicates intestinal inflammation in COVID-19. Gut. 2020;69:1543–4. DOI: 10.1136/gutjnl-2020-321388Quek S.X.Z., Loo E.X.L, Demutska A, Chua C.E., Kew G.S., Wong S., et al. Impact of the coronavirus disease 2019 pandemic on irritable bowel syndrome. J Gastroenterol Hepatol. 2021;36(8):2187–97. DOI: 10.1111/jgh.15466Quek S.X.Z., Loo E.X.L, Demutska A, Chua C.E., Kew G.S., Wong S., et al. Impact of the coronavirus disease 2019 pandemic on irritable bowel syndrome. J Gastroenterol Hepatol. 2021;36(8):2187–97. DOI: 10.1111/jgh.15466Nam Y., Kwon S.C., Lee Y.J., Jang E.C., Ahn S.H. Relationship between job stress and functional dyspepsia in display manufacturing sector workers: a cross-sectional study. Ann Occup Environ. Med. 2018;30:62. DOI: 10.1186/s40557-018-0274-4Nam Y., Kwon S.C., Lee Y.J., Jang E.C., Ahn S.H. Relationship between job stress and functional dyspepsia in display manufacturing sector workers: a cross-sectional study. Ann Occup Environ. Med. 2018;30:62. DOI: 10.1186/s40557-018-0274-4Felstead A., Henseke G. Assessing the growth of remote working and its consequences for effort, well-being and work-life balance. New Technol Work Employ. 2017;32(3):195–212. DOI: 10.1111/ntwe.12097Felstead A., Henseke G. Assessing the growth of remote working and its consequences for effort, well-being and work-life balance. New Technol Work Employ. 2017;32(3):195–212. DOI: 10.1111/ntwe.12097Oshima T., Siah K.T.H., Yoshimoto T., Miura K., Tomita T., Fukui H., et al. Impacts of the COVID-19 pandemic on functional dyspepsia and irritable bowel syndrome: A population-based survey. J Gastroenterol Hepatol. 2021;36(7):1820–7. DOI: 10.1111/jgh.15346Oshima T., Siah K.T.H., Yoshimoto T., Miura K., Tomita T., Fukui H., et al. Impacts of the COVID-19 pandemic on functional dyspepsia and irritable bowel syndrome: A population-based survey. J Gastroenterol Hepatol. 2021;36(7):1820–7. DOI: 10.1111/jgh.15346Scarmozzino F., Visioli F. Covid-19 and the subsequent lockdown modified dietary habits of almost half the population in an Italian sample. Foods 2020;9(5):675. DOI: 10.3390/foods9050675Scarmozzino F., Visioli F. Covid-19 and the subsequent lockdown modified dietary habits of almost half the population in an Italian sample. Foods 2020;9(5):675. DOI: 10.3390/foods9050675Hislop T.G., Bajdik C.D., Balneaves L.G., et al. Physical and emotional health effects and social consequences after participation in a low-fat, high-carbohydrate dietary trial for more than 5 years. J Clin Oncol. 2006;24(15):2311–7. DOI: 10.1200/JCO.2005.04.3042Hislop T.G., Bajdik C.D., Balneaves L.G., et al. Physical and emotional health effects and social consequences after participation in a low-fat, high-carbohydrate dietary trial for more than 5 years. J Clin Oncol. 2006;24(15):2311–7. DOI: 10.1200/JCO.2005.04.3042Liese A.D., Weis K.E., Pluto D., Smith E., Lawson A. Food store types, availability, and cost of foods in a rural environment. J Am Diet Assoc. 2007;107(11):1916–23. DOI: 10.1016/j.jada.2007.08.012Liese A.D., Weis K.E., Pluto D., Smith E., Lawson A. Food store types, availability, and cost of foods in a rural environment. J Am Diet Assoc. 2007;107(11):1916–23. DOI: 10.1016/j.jada.2007.08.012Barrett J.S. Extending our knowledge of fermentable, short-chain carbohydrates for managing gastrointestinal symptoms. Nutr Clin Pract. 2013;28(3):300–6. DOI: 10.1177/0884533613485790Barrett J.S. Extending our knowledge of fermentable, short-chain carbohydrates for managing gastrointestinal symptoms. Nutr Clin Pract. 2013;28(3):300–6. DOI: 10.1177/0884533613485790Coroiu A., Moran C., Campbell T., Geller A.C. Barriers and facilitators of adherence to social distancing recommendations during COVID-19 among a large international sample of adults. PLoS One. 2020;15:e0239795. DOI: 10.1371/journal.pone.0239795Coroiu A., Moran C., Campbell T., Geller A.C. Barriers and facilitators of adherence to social distancing recommendations during COVID-19 among a large international sample of adults. PLoS One. 2020;15:e0239795. DOI: 10.1371/journal.pone.0239795Alzahrani M.A., Alshamrani A.S., Ahmasani I.M., Alahmari F.S., Asiri A.H., Alshehri A.M. Coronavirus disease 2019 pandemic stress and its effects on irritable bowel syndrome patients in Saudi Arabia. Medicine (Baltimore). 2020;99(51):e23711. DOI: 0.1097/MD.0000000000023711Alzahrani M.A., Alshamrani A.S., Ahmasani I.M., Alahmari F.S., Asiri A.H., Alshehri A.M. Coronavirus disease 2019 pandemic stress and its effects on irritable bowel syndrome patients in Saudi Arabia. Medicine (Baltimore). 2020;99(51):e23711. DOI: 0.1097/MD.0000000000023711Conte L., Toraldo D.M. Targeting the gut-lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection. Ther Adv Respir Dis. 2020;14:1753466620937170. DOI: 10.1177/1753466620937170Conte L., Toraldo D.M. Targeting the gut-lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection. Ther Adv Respir Dis. 2020;14:1753466620937170. DOI: 10.1177/1753466620937170Mehtab W., Agarwal A., Singh N., Malhotra A., Makharia G.K. All that a physician should know about FODMAPs. Indian J Gastroenterol 2019;38:378–90. DOI: 10.1007/s12664-019-01002-0Mehtab W., Agarwal A., Singh N., Malhotra A., Makharia G.K. All that a physician should know about FODMAPs. Indian J Gastroenterol 2019;38:378–90. DOI: 10.1007/s12664-019-01002-0Ghoshal U.C. Pros and cons while looking through an Asian window on the Rome IV criteria for irritable bowel syndrome: pros. J Neurogastroenterol Motil. 2017;23:334–40. DOI: 10.5056/jnm17020Ghoshal U.C. Pros and cons while looking through an Asian window on the Rome IV criteria for irritable bowel syndrome: pros. J Neurogastroenterol Motil. 2017;23:334–40. DOI: 10.5056/jnm17020Zhang Q., Yue S., Wang W., Chen Y., Zhao C., Song Y., et al. Potential Role of Gut Microbiota in Traditional Chinese Medicine against COVID-19. Am J Chin Med. 2021;49(4):785–803. DOI: 10.1142/S0192415X21500373Zhang Q., Yue S., Wang W., Chen Y., Zhao C., Song Y., et al. Potential Role of Gut Microbiota in Traditional Chinese Medicine against COVID-19. Am J Chin Med. 2021;49(4):785–803. DOI: 10.1142/S0192415X21500373d’Ettorre G., Ceccarelli G., Marazzato M., Campagna G., Pinacchio C., Alessandri F., et al. Challenges in the management of SARS-CoV2 Infection: The role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Front. Med. 2020;7:389. DOI: 10.3389/fmed.2020.00389d’Ettorre G., Ceccarelli G., Marazzato M., Campagna G., Pinacchio C., Alessandri F., et al. Challenges in the management of SARS-CoV2 Infection: The role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Front. Med. 2020;7:389. DOI: 10.3389/fmed.2020.00389Ивашкин В.Т., Маев И.В., Шелыгин Ю.А., Баранская Е.К., Белоус С.С., Белоусова Е.А. и др. Диагностика и лечение синдрома раздраженного кишечника (Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(5):74–95. DOI: 10.22416/1382-4376-2021-31-5-74-95Ivashkin V.T., Maev I.V., Shelygin Yu.A., Baranskaya E.K., Belous S.S., Belousova E.A., et al. Diagnosis and Treatment of Irritable Bowel Syndrome: Clinical Recommendations of the Russian Gastroenterological Association and Association of Coloproctologists of Russia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(5):74–95 (In Russ.). DOI: 10.22416/1382-4376-2021-31-5-74-95Эртузун И.А., Зуева Е.П., Клылова С.Г., Ефимова Л.А., Дугина Ю.Л., Эпштейн О.И. Экспериментальное изучение «Колофорта» — нового препарата для лечения синдрома раздраженного кишечника и других функциональных заболеваний желудочно-кишечного тракта. Вестник Волгоградского государственного медицинского университета. 2012;4(44):25–27.Ertuzun I.A., Zueva E.P., Klylova S.G., Efimova L.A., Dugina Yu.L., Epstein O.I. Experimental study of preparation Kolofort — a novel drug for treatment of irritable bowel syndrome and other functional gastrointestinal disorders. Vestnik VolgGMU. 2012;4(44):25–27 (In Russ.).Ivashkin V.T., Poluektova E.A., Glazunov A.B., Putilovskiy M.A., Epstein O.I. Pathogenetic approach to the treatment of functional disorders of the gastrointestinal tract and their intersection: results of the Russian observation retrospective program COMFORT. BMC Gastroenterol. 2019;20(1):2. DOI: 10.1186/s12876-019-1143-5Ivashkin V.T., Poluektova E.A., Glazunov A.B., Putilovskiy M.A., Epstein O.I. Pathogenetic approach to the treatment of functional disorders of the gastrointestinal tract and their intersection: results of the Russian observation retrospective program COMFORT. BMC Gastroenterol. 2019;20(1):2. DOI: 10.1186/s12876-019-1143-5

The authors declare that there are no conflicts of interest present.